top of page

Money on the Move: June 30 – July 6

Synthetic biology startup Antheia raised $73 million in Series B financing to support the company’s efforts to bring its first plant-based medicine to market and support the production of necessary active pharmaceutical ingredients and materials. The financing will enable the company to use its synthetic biology platform to engineer the molecules necessary to support the development of essential medications that rely on plant-based materials, avoiding the recurring supply disruptions from natural and man-made disasters.

Read the article at BioSpace

bottom of page